Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Savient On Track To Resubmit Krystexxa BLA In Early 2010, Exec Maintains

This article was originally published in The Pink Sheet Daily

Executive Summary

After a Sept. 14 meeting with the FDA, the biotech is confident it can satisfy all points in a complete response letter - including the gout therapy's REMS.

You may also be interested in...



After Lengthy Delay, Polaris Ready To Take HCC Drug Into Phase III

With an SPA, the Taiwan-financed, U.S.-based biotech hopes to obtain FDA approval in hepatocellular carcinoma with a single Phase III trial.

After Lengthy Delay, Polaris Ready To Take HCC Drug Into Phase III

With an SPA, the Taiwan-financed, U.S.-based biotech hopes to obtain FDA approval in hepatocellular carcinoma with a single Phase III trial.

Looking For A Buyer, Savient Talks Krystexxa Price & Gears Up For Launch

On the prowl for a buyer after the approval of Krystexxa for refractory gout, Savient Pharmaceuticals assured investors that they have enough product supply to launch by year-end and that it will set a premium price, though it was vague on when it will commit to an exact figure.

Related Content

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel